The European Patent Office intends to grant a new patent for IRLAB’s mesdopetam.

Gothenburg, Sweden, December 11, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the European Patent Office (EPO) intends to grant an additional patent for mesdopetam. The new patent covers various salt forms of the drug candidate.

IRLAB participates in Redeye Technology & Life Science Day on December 3, 2025

Nomination committee appointed for IRLAB’s annual general meeting 2026